Status:
COMPLETED
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
Lead Sponsor:
Bukwang Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
19-75 years
Phase:
PHASE3
Brief Summary
This is a study designed to evaluate the efficacy and safety of lurasidone in acutely psychotic patients with chronic schizophrenia and to confirm the non-inferiority of lurasidone relative to quetiap...
Eligibility Criteria
Inclusion
- Provide written informed consent and aged between 19 and 75 years of age.
- Meets DSM-5 criteria for a primary diagnosis of schizophrenia.
- CGI-S ≥ 4 at screening and baseline.
- Subject is not pregnant (must have a negative serum pregnancy test at screening) or nursing (must not be lactating) and is not planning pregnancy within the projected duration of the study.
- Subject is able and agrees to remain off prior antipsychotic medication for the duration of the study.
- Subject is in good physical health on the basis of medical history, physical examination, and laboratory screening.
Exclusion
- The subject has evidence of any chronic organic disease of the CNS (other than schizophrenia)
- Subject has participated in a prior trial of lurasidone.
- Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
- In the opinion of the investigator, subject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
- Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
Key Trial Info
Start Date :
April 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2022
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT03465787
Start Date
April 9 2018
End Date
October 26 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Borame Medical Center
Seoul, Seoul, Dongjak-gu, South Korea, 07061